# HAEMODYNAMIC FLOW TO THE HIP IN FEMALE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ITS CORRELATION WITH RISK FACTORS OF OSTEONECROSIS

Thesis

Submitted for partial fulfillment of M.D. degree in Rheumatology and Rehabilitation

Presented By

Nahla Naeem Mohamed Ali M.B.B.Ch.(M.Sc.)

## Supervised by

## Prof. Dr. Samia Zaki Hassan

Professor of Rheumatology & Rehabilitation Faculty of Medicine – Cairo University

## Prof. Dr. Mayada Ali Abd-Allah

Professor of Rheumatology & Rehabilitation Faculty of Medicine – Cairo University

## Prof. Dr. Hatem M.S. El-Azizi

Professor of Radiodiagnosis Faculty of Medicine – Cairo University

### Faculty of Medicine Cairo University 2010

# **DEDICATION**

To my parents who taught me everything I know, for their love, care and advise which were always there to support and encourage me in every moment of my life.

To my husband, daughter and son for their great tolerance, strong support and persistant understanding.

To my brother for his eare and support.

Last, but never least to my father Prof. Dr.Nagem Cesa for his undug help, unlimited support, guidance, patience and precious advise. I can never express my appreciation for him, to you I dedicate this work trying to say thank you so much.

NAHLA NACCM

### Abstract

Osteonecrosis is strongly associated with systemic lupus erythematosus. The hip, and in particular the femoral head, is the most commonly encountered type. Glucocorticoids as well as disease associated factors have been proposed to enhance the risk for osteonecrosis development. This study aims to evaluate haemodynamic changes in the femoral head in patients with SLE before the development of osteonecrosis and determine the effect of the various risk factors of osteonecrosis on haemodynamic flow. This study was conducted on fourty consecutive female patients with systemic lupus erythematosus and twenty healthy volunteers, whom underwent clinical assessment, laboratory investigations as well as colour & power doppler ultrasound of the blood vessels (medial & lateral circumflex femoral arteries) supplying the femoral head bilaterally. From this study we concluded that hemodynamic flow to the hip is already altered in SLE patients without ON, and the presence of associated risk factors of ON contribute to more haemodynamic flow alteration.

#### Key words:

Systemic Lupus Erythematosus, Osteonecrosis, Hip joint, Risk factors.

## CONTENTS

Page

ACKNOWLEDGEMENTS	•••• ii
LIST OF ABBREVIATIONS LIST OF FIGURES LIST OF TABLES INTRODUCTION AND AIM OF THE WORK	vi ix
<b>REVIEW OF LITERATURE</b>	5
Systemic Lupus Erythematosus	5
Anatomy of the Hip Joint	35
Osteonecrosis of the Femoral Head	49
Osteonecrosis in Systemic Lupus Erythematosus	78
Haemodynamics of Blood Flow to the Femoral Head	87
PATIENTS AND METHODS	98
RESULTS	116
DISCUSSION	136
SUMMARY AND CONCLUSION	. 151
REFERENCES	<b></b> 154
ARABIC SUMMARY	. 176

### ACKNOWLEDGEMENTS

S would like to express my profound gratitude and immense appreciation to Prof Dr. Samia Zaki Hassan, professor of Rheumatology and Rehabilitation, Cairo University, for her keen interest in the progress of this work, her constructive criticism as well as her great patience in reading and revising the manuscripts. She was very generouse in providing me with her knowledge and scientific materials.

Sincere thanks are due to Prof Dr. Mayada Ali Abd-allah, professor of Rheumatology and Rehabilitation, Cairo University, for her helpful suggestions and valuable advice.

Special thanks are due to Prof Dr. Hatem Mohamed Said El-Azizi, professor of Radiodiagnosis, Cairo University, for his great assistance in the radiologic studies.

S must thank the team of the laboratories of Clinical and Chemical Pathology Department, Cairo University Kospitals for carrying out laboratory investigations of patients under study.

# LIST OF ABBREVIATIONS

ACEAngiotensin Converting EnzymeACRAmerican College of RheumatologyALTAlanine TransaminaseANAAnti Nuclear AntibodyANCAAnti Nuclear AntibodyANCAAnti Neutrophil Cytoplasmic AntibodyAnti ds-DNAAnti double stranded deoxyribonucleic acidAnti-SmAnti SmithAPLAntiphospholipid antibodiesAPSAntiphospholipid SyndromeAPTTActivated partial thromboplastin timeARCOAssociation of Research Circulation OsseousASISAnterior Superior Illiac SpineASTAspartate TransaminaseAVNAvascular NecrosisCADCoronary Artery DiseaseCBCComplete Blood CountCCDCaput Collom DiaphysealCLECutaneous Lupus ErythematosusCNSCentral Nervous SystemCRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic CellsDJDDegenerative Joint Disease		
ALTAlanine TransaminaseANAAnti Nuclear AntibodyANCAAnti Neutrophil Cytoplasmic AntibodyAnti ds-DNAAnti double stranded deoxyribonucleic acidAnti-SmAnti SmithAPLAntiphospholipid antibodiesAPSAntiphospholipid SyndromeAPTTActivated partial thromboplastin timeARCOAssociation of Research Circulation OsseousASISAnterior Superior Illiac SpineASTAspartate TransaminaseAVNAvascular NecrosisCADCoronary Artery DiseaseCBCComplete Blood CountCCDCaput Collom DiaphysealCLECutaneous Lupus ErythematosusCNSCentral Nervous SystemCRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	ACE	Angiotensin Converting Enzyme
ANAAnti Nuclear AntibodyANCAAnti Neutrophil Cytoplasmic AntibodyAnti ds-DNAAnti double stranded deoxyribonucleic acidAnti - SmAnti SmithAPLAntiphospholipid antibodiesAPSAntiphospholipid SyndromeAPTActivated partial thromboplastin timeARCOAssociation of Research Circulation OsseousASISAnterior Superior Illiac SpineASTAspartate TransaminaseAVNAvascular NecrosisCADCoronary Artery DiseaseCBCComplete Blood CountCCDCaput Collom DiaphysealCLECutaneous Lupus ErythematosusCNSCentral Nervous SystemCRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	ACR	American College of Rheumatology
ANCAAnti Neutrophil Cytoplasmic AntibodyAnti ds-DNAAnti double stranded deoxyribonucleic acidAnti-SmAnti SmithAPLAntiphospholipid antibodiesAPSAntiphospholipid SyndromeAPTActivated partial thromboplastin timeARCOAssociation of Research Circulation OsseousASISAnterior Superior Illiac SpineASTAspartate TransaminaseAVNAvascular NecrosisCADCoronary Artery DiseaseCBCComplete Blood CountCCDCaput Collom DiaphysealCLECutaneous Lupus ErythematosusCNSCentral Nervous SystemCRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	ALT	Alanine Transaminase
Anti ds-DNAAnti double stranded deoxyribonucleic acidAnti- SmAnti SmithAPLAntiphospholipid antibodiesAPSAntiphospholipid SyndromeAPTTActivated partial thromboplastin timeARCOAssociation of Research Circulation OsseousASISAnterior Superior Illiac SpineASTAspartate TransaminaseAVNAvascular NecrosisCADCoronary Artery DiseaseCBCComplete Blood CountCCDCaput Collom DiaphysealCLECutaneous Lupus ErythematosusCNSCentral Nervous SystemCRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	ANA	Anti Nuclear Antibody
Anti-SmAnti SmithAPLAntiphospholipid antibodiesAPSAntiphospholipid SyndromeAPTTActivated partial thromboplastin timeARCOAssociation of Research Circulation OsseousASISAnterior Superior Illiac SpineASTAspartate TransaminaseAVNAvascular NecrosisCADCoronary Artery DiseaseCBCComplete Blood CountCCDCaput Collom DiaphysealCLECutaneous Lupus ErythematosusCNSCentral Nervous SystemCRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	ANCA	Anti Neutrophil Cytoplasmic Antibody
APLAntiphospholipid antibodiesAPSAntiphospholipid SyndromeAPTTActivated partial thromboplastin timeARCOAssociation of Research Circulation OsseousASISAnterior Superior Illiac SpineASTAspartate TransaminaseAVNAvascular NecrosisCADCoronary Artery DiseaseCBCComplete Blood CountCCDCaput Collom DiaphysealCLECutaneous Lupus ErythematosusCNSCentral Nervous SystemCRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	Anti ds-DNA	Anti double stranded deoxyribonucleic acid
APSAntiphospholipid SyndromeAPTTActivated partial thromboplastin timeARCOAssociation of Research Circulation OsseousASISAnterior Superior Illiac SpineASTAspartate TransaminaseAVNAvascular NecrosisCADCoronary Artery DiseaseCBCComplete Blood CountCCDCaput Collom DiaphysealCLECutaneous Lupus ErythematosusCNSCentral Nervous SystemCRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	Anti- Sm	Anti Smith
APTTActivated partial thromboplastin timeARCOAssociation of Research Circulation OsseousASISAnterior Superior Illiac SpineASTAspartate TransaminaseAVNAvascular NecrosisCADCoronary Artery DiseaseCBCComplete Blood CountCCDCaput Collom DiaphysealCLECutaneous Lupus ErythematosusCNSCentral Nervous SystemCRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	APL	Antiphospholipid antibodies
ARCOAssociation of Research Circulation OsseousASISAnterior Superior Illiac SpineASTAspartate TransaminaseAVNAvascular NecrosisCADCoronary Artery DiseaseCBCComplete Blood CountCCDCaput Collom DiaphysealCLECutaneous Lupus ErythematosusCNSCentral Nervous SystemCRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	APS	Antiphospholipid Syndrome
ASISAnterior Superior Illiac SpineASTAspartate TransaminaseAVNAvascular NecrosisCADCoronary Artery DiseaseCBCComplete Blood CountCCDCaput Collom DiaphysealCLECutaneous Lupus ErythematosusCNSCentral Nervous SystemCRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	APTT	Activated partial thromboplastin time
ASTAspartate TransaminaseAVNAvascular NecrosisCADCoronary Artery DiseaseCBCComplete Blood CountCCDCaput Collom DiaphysealCLECutaneous Lupus ErythematosusCNSCentral Nervous SystemCRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	ARCO	Association of Research Circulation Osseous
AVNAvascular NecrosisCADCoronary Artery DiseaseCBCComplete Blood CountCCDCaput Collom DiaphysealCLECutaneous Lupus ErythematosusCNSCentral Nervous SystemCRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	ASIS	Anterior Superior Illiac Spine
CADCoronary Artery DiseaseCBCComplete Blood CountCCDCaput Collom DiaphysealCLECutaneous Lupus ErythematosusCNSCentral Nervous SystemCRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	AST	Aspartate Transaminase
CBCComplete Blood CountCCDCaput Collom DiaphysealCLECutaneous Lupus ErythematosusCNSCentral Nervous SystemCRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	AVN	Avascular Necrosis
CCDCaput Collom DiaphysealCLECutaneous Lupus ErythematosusCNSCentral Nervous SystemCRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	CAD	Coronary Artery Disease
CLECutaneous Lupus ErythematosusCNSCentral Nervous SystemCRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	CBC	Complete Blood Count
CNSCentral Nervous SystemCRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	CCD	Caput Collom Diaphyseal
CRPC- reactive proteinCSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	CLE	Cutaneous Lupus Erythematosus
CSCorticosteroidsCTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	CNS	Central Nervous System
CTComputed TomographyCVACerebrovascular AccidentDCDendritic Cells	CRP	C- reactive protein
CVA Cerebrovascular Accident   DC Dendritic Cells	CS	Corticosteroids
DC Dendritic Cells	СТ	Computed Tomography
	CVA	Cerebrovascular Accident
DJD Degenerative Joint Disease	DC	Dendritic Cells
	DJD	Degenerative Joint Disease
DMARDSDisease Modifiying Anti Rheumatic Drugs	DMARDS	Disease Modifiying Anti Rheumatic Drugs
DNA Deoxyribonucleic acid	DNA	Deoxyribonucleic acid
EBV Ebstein Barr Virus	EBV	Ebstein Barr Virus

ECG	Electrocardiogram
EDV	End Diastolic Velocity
ELISA	Enzyme Linked Immunosorbant Assay
ENA	Extractable Nuclear Antigen
ESR	Erythrocyte Sedimentation Rate
EULAR	European League Against Rheumatism
FDA	Food and Drug Administration
FDC	Follicular Dendritic Cells
GC	Germinal Centres
HDL	High Density Lipoprotein
HIV	Human immunodeficiency virus
HLA	Human Leucocyte Antigen
HMGB1	High Mobility Group Box 1
Ig G	Immunoglobulin G
Ig M	Immunoglobulin M
IVIG	Intravenous Immunoglobulin
LCF	Lateral Circumflex Femoral
LDL	Low Density Lipoprotein
LEVs	Lateral Epiphyseal Vessels
Max	Maximum
MCF	Medial Circumflex Femoral
mg	milligrams
МНС	Major Histocompatibility Complex
Min	Minimum
MRA	Magnetic Resonance Angiograohy
MRI	Magnetic Resonance Imaging
NSAIDs	Non steroidal anti-inflammatory drugs
ON	Osteonecrosis
Op-1	Osteogenic protein-1
PI	Pulsatility Index

PSV	Peak Systolic Velocity
RBCs	Red Blood Cells
rhBMP-2	Recombinant human Bone Morphogenetic Protein-2
RI	Resistivity Index
RNP	Ribonucleoprotein
ROM	Range of Motion
S/D	Systolic to Diastolic ratio
SCD	Sickle Cell Disease
SD	Standard Deviation
SLE	Systemic Lupus Erythematosus
SLEDAI	Systemic Lupus Erythematosus Disease Activity Index
SLICC/ACR	Systemic Lupus International Collaboration
	Clinics/ACR damage index
SPECT	Single Photon Emission Computed Tomography
ТВ	Tuberculosis
TBMs	Tingible Body Macrophages
TGs	Triglycerides
THA	Total Hip Arthroplasty
TNF	Tumour Necrosis Factor
ТТР	Thrombotic thrombocytopenic purpura
US	Ultrasound
UV	Ultraviolet
WBCs	White Blood Cells

# LIST OF FIGURES

No.	Description	Page
Fig. (1)	Risk factors in the development of SLE	5
Fig. (2)	Pathophysiology of SLE	8
Fig. (3)	Clinical manifestations of SLE	12
<b>Fig.</b> (4)	Hip joint; ball & socket variety	35
Fig. (5)	Changes in trabecular patterns due to altered CCD angle.	36
<b>Fig.</b> (6)	Section through a hip joint	38
<b>Fig.</b> (7)	Fibrous capsule and ligaments of the hip joint	40
<b>Fig. (8)</b>	Ligamentum Teres (Intraarticular ligament)	41
<b>Fig.</b> (9)	Arteries supplying the hip joint	45
<b>Fig.</b> (10)	Medial & Lateral circumflex femoral arteries	48
<b>Fig.</b> (11)	Interuption of the blood supply to the femoral head	49
	resulting in bone necrosis & collapse	
<b>Fig.</b> (12)	Plain radiograph, frogleg lateral view of the left hip in a	56
	patient with avascular necrosis showing the crescent sign	
<b>Fig.</b> (13)	Plain radiograph, anteroposterior view of the pelvis	57
	showing flattening of the outer portion of the right	
	femoral head from avascular necrosis	
<b>Fig.</b> (14)	Coronal T1-weighted MR image showing decreased	58
	signal intensity in both femoral heads in the	
	subchondral region (water signal)	

<b>Fig.</b> (15)	Coronal T2-weighted MR image necrosis of the	59
	femoral head showing the double-line sign within the	
	left femoral head	
Fig. (16)	Planar bone scan of the pelvis in a patient with bilateral	62
	avascular necrosis of the femoral head showing	
	marked increased uptake in both hips	
<b>Fig.</b> (17)	Axial CT scan of a patient with avascular necrosis of	64
	the femoral head showing clumping and distortion of	
	the central trabeculae representing the asterisk sign	
	(arrowhead) and an adjacent low-density region (arrow)	
	representing the reparative zone	
Fig. (18)	Ohzono Prognostic Classification	68
Fig. (19)	Anteroposterior view of the left hip in a patient with	73
	avascular necrosis that has undergone core	
	decompression	
Fig. (20)	Anteroposterior view of the right hip in a patient with	77
	avascular necrosis that has undergone limited femoral	
	resurfacing	
<b>Fig.</b> (21)	A schematic diagram of the continuous-wave Doppler	88
	instrument.	
<b>Fig.</b> (22)	a) Concept of color flow imaging.	91
	<b>b</b> ) Color flow image shows flow in a vessel of a	
	doppler phantom.	
Fig. (23)	Color flow (top) and power doppler (bottom) images of	92
	the same phantom under the same conditions.	
-	•	

Fig. (24)	<b>a</b> ) Laminar flow in a vessel of radius <i>r</i> .	94
	<b>b</b> ) Flow in a typical blood vessel follows a blunt	
	profile.	
Fig. (25)	Pulsed-wave US spectrum displays the maximum,	97
	minimum, and average calculated blood flow	
	velocities.	
Fig. (26)	Clinical manifestations of SLE patients under study	118
Fig. (27)	Comparison of mean values of the PSV and PI between	126
	SLE patients and healthy controls in the neutral	
	position	
Fig. (28)	Comparison of mean values of the PSV and PI between	130
	SLE patients and healthy controls after internal rotation	
Fig. (29)	Comparison of the PSV (A) and PI (B) between SLE	132
	patients and healthy controls in the neutral position and	
	after internal rotation	

# LIST OF TABLES

No	•	Description	Page
Table	(1)	International Society of Nephrology 2003 Revised	25
		Classification of SLE Nephritis	
Table	(2)	Ficat and Arlet staging system of ON	66
Table	(3)	Steinberg staging system of ON	67
Table	(4)	ARCO International Classification of ON	69
Table	(5)	Risk factors associated with the development of ON in patients with SLE.	82
Table	(6)	The list form of ACR criteria for classification of SLE	98
Table	(7)	Normal values of the range of motion of the hip joint	107
Table	(8)	SLE disease activity index (SLEDAI)	111
Table	(9)	SLICC/ACR Damage index	113
Table	(10)	Clinical manifestations of SLE patients under study	117
Table	(11)	Laboratory features of SLE patients under study	121
Table	(12)	Disease activity and damage in SLE patients under study	121
Table	(13)	Dose and duration of corticosteroid usage amoung SLE patients under study	122
Table	(14)	The mean values of the PSV and PI in SLE patients and healthy controls in the neutral position	124
Table	(15)	Comparison of mean values of the PSV and PI between group A and B SLE patients in the neutral position	125
Table	(16)	Comparison of mean values of the PSV and PI between group B SLE patients and healthy controls in the neutral position	125
Table	(17)	Comparison of mean values of the PSV and PI between group A SLE patients and healthy controls in the	126

	neutral position	
Table (18)	The mean values of the PSV and PI in SLE patients and	128
	healthy controls after internal rotation of the femoral head	
	(stimulated ischemia)	
Table (19)	Comparison of mean values of the PSV and PI between	129
	group A and B SLE patients after internal rotation	127
T-11- (20)	Comparison of mean values of the PSV and PI between	120
Table (20)	_	129
	group B SLE patients and healthy controls after internal	
	rotation	
Table (21)	Comparison of mean values of the PSV and PI between	130
	group A SLE patients and healthy controls after internal	
	rotation.	
Table (22)	Comparison of the PSV and PI between SLE patients and	131
Table (22)		151
	healthy controls in the neutral position and after internal	
	rotation	
Table (23)	Correlation between PI and studied variables in SLE	134
	group A patients	
Table (24)	Correlation between PI and studied variables in SLE	135
	group B patients	155
	Stoup D putients	

## **INTRODUCTION**

Osteonecrosis (ON) is a clinical entity of an unclear pathogenisis characterized by death of the bone marrow and the trabecular bone. It often results in the collapse of the architectural bone structure, leading to joint pain and loss of function. Circulatory impairment of the affected bone has been postulated to be the common denominator for all cases of ON (Filaho *et al.*, 2007).

The term "avascular necrosis" describes the occurance of osteonecrosis in the epiphysis. When the same process involves the metaphysis or diaphysis the term "bone infarct" is applied (**Watson** *et al.*, **2004**). Avascular necrosis occurs in a number of conditions usually involving the epiphysis of long bones, such as the femoral and humeral heads and the femoral condyles, but small bones and the vertebrae can also be affected. The anterolateral aspect of the femoral head, the principle weightbearing region and the site of greatest mechanical stress, typically is involved, but no region of the femoral head is necessarily spared (**Sharma** *et al.*, **2003**).

Osteonecrosis may be due to a traumatic insult with interruption of the vascular supply or non-traumatic in conditions that result in vascular occlusion or increased intraosseous pressure (**Aranow** *et al.*, **1997**). The pathogenesis of non-traumatic ON of the femoral head has been suggested by vascular occlusion, thrombophilia, altered fat metabolism and fat emboli, elevated intracortical pressure, inhibition of angiogenesis, intramedullary haemorrhage, mechanical stress and primary cell death (**Abu-Shakra** *et al.*, **2003**).

Among the rheumatic diseases, ON is strongly associated with systemic lupus erythematosus (SLE). Most investigators have found the use of glucocorticoids to be a major risk factor for ON in SLE (Nagasawa *et al.*, 2005). Osteonecrosis of the hip, and in particular the femoral head, is the most commonly encountered type in clinical practice

(Steinberg, 1999). In SLE symptomatic ON has been reported in 10-12% of patients (Gladman *et al.*, 2001). It has been reported to occur within four years of diagnosis in at least 80% of cases (Park *et al.*, 2007). However, ON has also been reported in lupus patients whom have never received therapy with this drug (Zonana *et al.*, 2000) Moreover, a significant lower frequency of ON has been reported in other clinical conditions requiring chronic corticosteroid therapy (Zizic, 1990). Alternatively, disease associated factors have been proposed to enhance the risk for ON development, such as: disease activity, vasculitis, Raynaud's phenomenon, thrombophlebitis, antiphospholipid antibodies or syndrome, thrombophilia and hypofibrinolysis (Tektoniolou *et al.*, 2003). Among these, disease activity is perhaps the most difficult to elucidate, since most studies have not used standard instruments of measurement, and more importantly they have not evaluated flares at the time of or close to the clinical onset of ON (Gladman *et al.*, 2005)

Since joint preservation measures have a much better prognosis when the diagnosis of ON is made early in the course of the disease, and since the results of joint replacement therapy are poorer in younger age groups, diagnosing ON as early as possible is critical to prevent or delay progression of the disease (**Sharma** *et al.*, **2003**).

During the last years, magnetic resonance imaging (MRI) has proven to be the single method for the early diagnosis of ON. It is a very safe technique and is both very sensitive and very specific for ON (**Aiello** *et al.*, **2004**). MRI and bone scintigraphy are helpful for diagnosing early ON of the femoral head. However, no predictive test is known to detect ON (**Lee** *et al.*, **2007**).

Evaluation of haemodynamic flow to the femoral head is important in understanding how blood flow is closely related to intraosseous pressure and the pressure of the joint cavity (Launder *et al.*, 1981).